Big pharma shouldn’t be too greedy
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Big pharma shouldn’t be too greedy

Thoughts

Mihir Sharma, Bloomberg
07 August, 2020, 09:50 am
Last modified: 07 August, 2020, 10:03 am

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus

Big pharma shouldn’t be too greedy

If vaccine makers price their products too high for the developing world to access, it could blow up the whole idea of intellectual property

Mihir Sharma, Bloomberg
07 August, 2020, 09:50 am
Last modified: 07 August, 2020, 10:03 am
Big pharma shouldn’t be too greedy

Intellectual property is a convenient fiction. It is a right enforced by state power and international agreements, one that's even more fragile than other forms of property rights since it's not tangible.

We choose to believe this fiction because we also believe that intellectual property adds to general welfare. It permits innovation and growth, and supports writers, artists, inventors — and pharmaceutical companies.

But crises upend beliefs and we are in a crisis at the moment. We should all hope the tradition of treating intellectual property as a real thing survives the pandemic. That hope must be especially keen among the companies most at risk if the myth breaks down: the pharma industry.

Nothing is more likely to test this consensus than hints of profiteering off the war against Covid-19. A Financial Times report that the U.S.-based company Moderna Inc. has sought to price its vaccine candidate around $50-$60 per course, for example, has shaken public health establishments across the world. The story also suggested that while Moderna might offer developing countries a lower price, rich countries would get privileged access to the vaccine.

A successful vaccine could be a huge money-spinner. PHOTO: GETTY IMAGES/BLOOMBERG.
A successful vaccine could be a huge money-spinner. PHOTO: GETTY IMAGES/BLOOMBERG.

Let me tell you the consequences if that happens and Moderna's vaccine performs better than its cheaper competitors: The patent on the vaccine will be widely ignored. The consensus on intellectual property, painstakingly built up over time and spread worldwide over the past two decades, will be busted.

I don't want to single out Moderna here. It doesn't have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer Inc.'s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were "fanatic and radical." (AstraZeneca PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines, so Pfizer clearly has an odd definition of "fanatic and radical.")

If a vaccine proves too expensive or difficult to obtain, those who seek exorbitant profits off of it will be scrutinized far more closely than bankers were after the 2008 crash. Actions like those that have already allowed insiders to pocket $80 million will provoke public revulsion, even if those trades were pre-scheduled. Calls to regulate sectors that take for granted intellectual property protections will grow exponentially. Those demands won't be fanatical or radical, but mainstream.

It will be hard enough to preserve the myth of intellectual property within rich countries. Once international capital flows are involved, it'll be impossible. Cash-strapped governments around the world are not going to pay tens of billions for vaccines needed to save the lives of their citizens. Any attempts to collect using the traditional trading and legal architecture will be ignored — and will indeed lead to those institutions being seen as discredited or even immoral.

There is a lesson here that goes beyond the pandemic. If we are not sufficiently careful over the next decade, one likely economic future consists of tech lords, data czars and algorithm owners sitting in the U.S. or in China soaking up rents and payments from consumers in the rest of the world. That is simply unsustainable. Asian, African and even European governments will step in and prevent those streams of payments from being made. Global intellectual property requires the consent and enforcement of every state, not just one government. That consent will not be given if the capital flows involved appear to be one-way and permanent.

A world without global intellectual property would be one of constant electronic warfare. State-backed hacking, such as China apparently tried with Moderna this week, would be a constant threat. Nor would companies enjoy a comfortable relationship with their own governments, who would see them less as engines of growth and more as storehouses of national wealth and security. The days before copyright were tough. When the Murano glassmakers' industrial processes were considered state secrets in the Republic of Venice, the doges would kill any artisan who left the island.
That isn't a world we want to live in. It's up to pharma companies and rich-country governments to ensure that we're not forced to do so. The World Health Organization has asked those with relevant intellectual property to sign up to the Covid-19 Technology Access Pool, which will make vaccines broadly available across the world. Too few have.

Perhaps, as some pharma companies have done, IP holders can make it clear they will only seek to profit from their vaccines once the pandemic is over. A little patience would serve them — and the world — well in the long run.


Mihir Sharma is a Bloomberg Opinion columnist. He was a columnist for the Indian Express and the Business Standard, and he is the author of "Restart: The Last Chance for the Indian Economy."


Disclaimer: This article first appeared on Bloomberg.com, and is published by special syndication arrangement.


Top News

Pharma / Vaccine / Moderna Covid-19 Vaccine / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Corporates go cashless…tax cut on cards
    Corporates go cashless…tax cut on cards
  • Rising revenue collection a false dawn, economists say
    Rising revenue collection a false dawn, economists say
  • Why we must resist geoeconomic fragmentation—and how
    Why we must resist geoeconomic fragmentation—and how

MOST VIEWED

  • Your pilot may have had suicidal thoughts. And that’s ok: David Fickling
    Your pilot may have had suicidal thoughts. And that’s ok: David Fickling
  • Librarians are teachers, not clerks or booksellers
    Librarians are teachers, not clerks or booksellers
  • Philippine presidential candidate Ferdinand "Bongbong" Marcos Jr., son of late dictator Ferdinand Marcos, delivers a speech during a campaign rally in Lipa, Batangas province, Philippines. Photo: Reuters
    The echoes of America’s hypocrisy abroad
  • Infographic: TBS
    What really drives our low tax-to-GDP ratio! 
  • Shahadat Hussein
    How the culture of food waste impedes SDG attainment
  • Zhang Jun
    What justifies China’s zero-Covid policy?

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus

Features

Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

15h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

18h | Brands
Keep your phone by your side with this armband

Keep your phone by your side with this armband

16h | Brands
Are Focallure gel masks worth the hype?

Are Focallure gel masks worth the hype?

17h | Brands

More Videos from TBS

Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

10h | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

11h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

12h | Videos
Mosque of Mughal period in Gazipur

Mosque of Mughal period in Gazipur

12h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab